EX-23.1 11 d73463dex231.htm EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the use in this Registration Statement on Form S-1 of Seaport Therapeutics, Inc. of our report dated February 27, 2026, except for the effects of the reverse stock split discussed in Note 18 to the consolidated financial statements, as to which the date is April 27, 2026, relating to the financial statements of Seaport Therapeutics, Inc., which appears in this Registration Statement. We also consent to the reference to us under the heading “Experts” in such Registration Statement.

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts

April 27, 2026